AusPAR: Bevacizumab

Australian Public Assessment Report

AusPAR

Australian Public Assessment Report for Bevacizumab [PDF, 812.29 KB]

Australian Public Assessment Report for Bevacizumab [Word, 1.5 MB]

AusPAR Attachment 1: Product Information for Bevacizumab [PDF, 998.27 KB]

AusPAR Attachment 1: Product Information for Bevacizumab [Word, 609.81 KB]

Device/Product Name

Mvasi

Active ingredients

Bevacizumab

AusPAR Date

23 November 2020

Published

3 December 2020

Submission Number

PM-2017-04616-1-4

Submission Type

New biosimilar medicine

Decision

Approved